BA
ABBV icon

Bristlecone Advisors’s AbbVie ABBV Stock Holding History

Bristlecone Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$820K Buy
3,540
+2,033
+135% +$414K 0.07% 138
2025
Q2 		$280K Sell
1,507
-103
-6% -$19.1K 0.02% 193
2025
Q1 		$337K Sell
1,610
-255
-14% -$49.6K 0.03% 227
2024
Q4 		$331K Buy
1,865
+350
+23% +$64.3K 0.03% 230
2024
Q3 		$299K Sell
1,515
-286
-16% -$53.4K 0.02% 240
2024
Q2 		$309K Sell
1,801
-120
-6% -$19.9K 0.03% 228
2024
Q1 		$350K Hold
1,921
– – 0.03% 215
2023
Q4 		$298K Buy
1,921
+181
+10% +$26.4K 0.03% 227
2023
Q3 		$259K Sell
1,740
-8
-0.5% -$1.17K 0.03% 224
2023
Q2 		$236K Buy
1,748
+4
+0.2% +$587 0.02% 244
2023
Q1 		$278K Sell
1,744
-267
-13% -$40.8K 0.03% 219
2022
Q4 		$325K Sell
2,011
-382
-16% -$58.6K 0.04% 200
2022
Q3 		$321K Sell
2,393
-47
-2% -$6.74K 0.04% 195
2022
Q2 		$374K Sell
2,440
-4,344
-64% -$664K 0.05% 189
2022
Q1 		$1.1M Sell
6,784
-8
-0.1% -$1.16K 0.14% 115
2021
Q4 		$920K Buy
6,792
+2,125
+46% +$251K 0.11% 129
2021
Q3 		$503K Buy
4,667
+141
+3% +$16.1K 0.07% 153
2021
Q2 		$510K Buy
4,526
+554
+14% +$62.4K 0.07% 147
2021
Q1 		$430K Buy
+3,972
New +$425K 0.07% 150
2020
Q1 		– Sell
-5,938
Closed -$526K – 146
2019
Q4 		$526K Buy
+5,938
New +$493K 0.11% 132
2019
Q3 		– Sell
-5,336
Closed -$388K – 136
2019
Q2 		$388K Buy
+5,336
New +$419K 0.09% 136
2017
Q4 		– Sell
-1,275
Closed -$113K – 145
2017
Q3 		$113K Buy
+1,275
New +$97.1K 0.04% 162

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bristlecone Advisors's ABBV Position: Q3 2025 in Review

Bristlecone Advisors increased its AbbVie (ABBV) stake by 135% in Q3 2025, buying an estimated $414K and bringing the position to 3,540 shares worth $820K. The position accounts for 0.07% of the portfolio, ranked #138.

Bristlecone Advisors first reported a position in ABBV in Q3 2017 and has held it in 22 quarters since. The position peaked at $1.1M in Q1 2022. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Bristlecone Advisors held 3,540 shares of AbbVie worth $820K as of Q3 2025.
  • Bristlecone Advisors bought 2,033 AbbVie shares in Q3 2025, an estimated $414K.
  • AbbVie made up 0.07% of Bristlecone Advisors's portfolio in Q3 2025, its #138 holding.
  • Bristlecone Advisors first reported a position in AbbVie in Q3 2017 and has held it in 22 quarters since.
  • Bristlecone Advisors's AbbVie position peaked at $1.1M in Q1 2022.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.